Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

395
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
395
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

527
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
527
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

367
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Warfarin Prescribing Practices Nearing End of Life.

Thrombosis and haemostasis·2026
Same author

Direct Oral Anticoagulant Level Testing Before Surgery-Measure for Measure.

JAMA network open·2026
Same author

"Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation 2 pilot randomized trial": reply.

Journal of thrombosis and haemostasis : JTH·2025
Same author

In cancer-associated thrombosis, DOACs reduce VTE and increase clinically relevant nonmajor bleeding vs. LMWH at 3 to 12 mo.

Annals of internal medicine·2025
Same author

Direct oral anticoagulant management for neuraxial anaesthesia and deep peripheral nerve blocks.

British journal of anaesthesia·2025
Same author

Venous thromboembolism prevention and treatment with factor XI/XIa inhibitors: current status and future perspectives.

Journal of thrombosis and thrombolysis·2025

Related Experiment Video

Updated: Feb 21, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K

Navigating the anticoagulant landscape in 2017.

James D Douketis1,2,3

  • 1Professor of Medicine, McMaster University, Hamilton, ON, Canada.

Cleveland Clinic Journal of Medicine
|October 7, 2017
PubMed
Summary
This summary is machine-generated.

Managing blood thinners requires clear strategies. This review addresses optimal approaches for acute venous thromboembolism, surgical management with direct oral anticoagulants or warfarin, and the necessity of heparin bridging.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Related Experiment Videos

Last Updated: Feb 21, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Anticoagulant therapy is crucial for preventing and treating thromboembolic events.
  • Current guidelines leave several clinical questions regarding optimal management strategies unanswered.
  • Direct oral anticoagulants (DOACs) and warfarin are commonly used, each with unique management considerations.

Purpose of the Study:

  • To review and synthesize current evidence on managing acute venous thromboembolism.
  • To provide guidance on managing patients requiring elective surgery while on anticoagulation.
  • To clarify the indications for heparin bridging in specific clinical scenarios.

Main Methods:

  • Literature review of recent clinical trials and guidelines.
  • Analysis of evidence pertaining to anticoagulation strategies.
  • Synthesis of data to address key clinical management questions.

Main Results:

  • Evidence supports specific anticoagulation regimens for acute venous thromboembolism.
  • Strategies for perioperative management with DOACs and warfarin vary based on procedure risk.
  • Heparin bridging is often not necessary and may increase bleeding risk.

Conclusions:

  • Optimal management of acute venous thromboembolism involves tailored anticoagulation.
  • Perioperative anticoagulation requires careful planning, often avoiding bridging.
  • Further research is needed to refine anticoagulation protocols and address remaining uncertainties.